𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

✍ Scribed by T.-T. Chang; Y.-C. Chao; V. V. Gorbakov; K.-h. Han; R. G. Gish; R. De Man; H. Cheinquer; F. Bessone; H. Brett-Smith; R. Tamez

Book ID
108886293
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
145 KB
Volume
16
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Long-term monitoring shows hepatitis B v
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
✍ Daniel J. Tenney; Ronald E. Rose; Carl J. Baldick; Kevin A. Pokornowski; Betsy J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 742 KB

Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the